Abcellera Biologics Inc.

AbCellera Biologics leverages AI‑powered antibody discovery to target unmet medical needs in the U.S., with preclinical candidates ABCL635 (metabolic) and ABCL575 (autoimmune). Strategic partner with Eli Lilly, Biogen, and investment backing from Viking Global.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 596
HQ: Vancouver

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ABCL	Abcellera Biologics Inc. Cap: 1.3B	EQUITY	NMS	USD	CA00288U1066	Active	📈